Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Xu, J.M.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(9)
+
-
Availability
Metadata Only
(9)
+
-
Creation Date
2013
(4)
+
-
2012
(3)
+
-
2014
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(9)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(9)
+
-
Author
Badalamenti, G.
(9)
+
-
Blay, J.Y.
(9)
+
-
Casali, P.G.
(9)
+
-
Demetri, G.D.
(9)
+
-
Gelderblom, H.
(9)
+
-
Hohenberger, P.
(9)
+
-
Joensuu, H.
(9)
+
-
Kang, Y.K.
(9)
+
-
Kuss, I.
(9)
+
-
Maki, R.G.
(9)
+
-
Mehren, M. von
(9)
+
-
Nishida, T.
(9)
+
-
Reichardt, P.
(9)
+
-
Rutkowski, P.
(9)
+
-
Schoffski, P.
(9)
+
-
Xu, J.M.
(9)
+
-
Cesne, A. le
(8)
+
-
Blackstein, M.E.
(7)
+
-
Leahy, M.G.
(7)
+
-
Laurent, D.
(5)
+
-
Kappeler, C.
(4)
+
-
Jeffers, M.
(3)
+
-
Bauer, S.
(2)
+
-
Blackstein, M.
(2)
+
-
Chung, J.
(2)
+
-
GRID Invest
(2)
+
-
Leahy, M.
(2)
+
-
Nguyen, B.B.
(2)
+
-
Show more
Language
en
(9)
+
-
Search results
(1 - 9 of 9)
show grid
show list
save search
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) Subgroup analysis of outcomes based on pretreatment characteristics
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial